Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the
world causing a pandemic known as coronavirus disease 2019 (COVID-19). Cytokine storm …

Background The severity of COVID-19 is associated with an elevated level of a variety of
inflammatory mediators. Increasing evidence suggests that the Th17 response contributes to …

A significant proportion of COVID-19 patients will progress to critical illness requiring
invasive mechanical ventilation. This accentuates the need for a therapy that can reduce the …

The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
generated many challenges to find an effective drug combination for hospitalized patients …

Remdesivir is one of the most attractive options for patients with hypoxemic respiratory
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …

Remdesivir (RDV) has demonstrated clinical benefit in hospitalized COronaVIrus Disease
(COVID)-19 patients. The objective of this brief report was to assess a possible correlation …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes
coronavirus disease 2019 (COVID-19) has infected 86, 4 M patients and resulted in 1, 86 M …

Materials and Methods: A hospital-based prospective longitudinal study was conducted over
two months comprising event monitoring of COVID-19 patients administered remdesivir as …

Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly
spread across many other countries. While the majority of patients were considered mild …

Rationale: Coronavirus disease (COVID-19) is a global threat to health. Its inflammatory
characteristics are incompletely understood. Objectives: To define the cytokine profile of …